Report : Asia Pacific Hematuria Treatment Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Treatment (Drugs, Therapies, and Others), Indication (Urinary Tract Infections, Kidney Stones, Urethritis, Blood Cancer, Bladder Stones, Prostate Cancer, Cystitis, Trauma, Vigorous Exercise, Polycystic Kidney Disease, Endometriosis, and Menstruation), Type (Macroscopic Hematuria, Microscopic Hematuria, Idiopathic Hematuria, and Jogger’s Hematuria), End User (Hospitals, Clinics, and Ambulatory Surgical Centers, and Others)
Macroscopic Hematuria Segment has the Largest Share of Type in the Asia Pacific Hematuria Treatment Market during 2021–2028
According to our latest study on “Asia Pacific Hematuria Treatment Market Forecast to 2028 – COVID-19 Impact and Analysis – by Type, Treatment, Indication, and End User,” the market is projected to reach US$ 257.6 million by 2028 from US$ 211.0 million in 2021; it is expected to grow at a CAGR of 2.9% from 2021 to 2028. The report highlights trends prevailing in the market, and the drivers and restraints pertaining to the market growth. The growth of this market is estimated to grow owing to key driving factors such as the high prevalence of hematuria- associated indications, increasing awareness about treatment options and improving healthcare expenditure are factors propelling the hematuria treatment market. However, the undiagnosed cases of associated indications may hamper the growth of the Asia Pacific hematuria treatment market in the forecast period.
The COVID-19 outbreak has severely affected the tourism industry and imposed supply chain disruptions; moreover, low-income countries face additional challenges due to the shortage of healthcare infrastructure. Restrictive measures have been put forth in South Korea, Malaysia, Singapore, the Philippines, and India to prevent disease transmission. All these factors impacted moderately on hematuria treatment market for a short period of time due to restrictions on the supply chain as well as limited manufacturing capabilities. Renal involvement in COVID -19 patients may have a wide range of manifestations, including hematuria, proteinuria, pyuria, and acute kidney injury (AKI). Proteinuria and hematuria have been reported to have a higher prevalence of COVID 19 than AKI. On the other hand, AKI is currently a disturbing sign of hospitalized COVID 19 patients and a major risk factor for death. Therefore, the hematuria treatment market is positively affected by COVID19.
Based on type, the Asia Pacific hematuria treatment market is bifurcated into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. In 2021, the macroscopic hematuria segment is estimated to account for the largest market share. However, microscopic hematuria segment is estimated to register the highest CAGR during forecast period. Macroscopic hematuria is also known as gross hematuria. It is diagnosed by various methods such as blood tests, kidney biopsy, and others diagnosis techniques.
AstraZeneca, Bristol-Myers Squibb Company, F. HOFFMANN-LA ROCHE LTD., GlaxoSmithKline plc., Janssen Pharmaceuticals, Merck & Co., Inc., Novartis AG, Pfizer Inc.,Sun Pharmaceutical Industries Ltd, and Boehringer Ingelheim International GmbH are among the leading companies in the Asia Pacific hematuria treatment market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, AstraZeneca, in September 2021, the new plant will allow for late-stage development and early commercial supply, adopting state of the art process technology and digital innovation that is designed to meet the needs of the Company’s new medicines pipeline with speed and agility.
The market for hematuria treatment market is segmented into type, treatment, Indication, and end user. Based on type, the Asia Pacific hematuria treatment market is segmented into macroscopic hematuria, microscopic hematuria, idiopathic hematuria, and jogger’s hematuria. Based on treatment, the hematuria treatment market is segmented drugs, therapies, and others. Based on indication, the hematuria treatment market is segmented into urinary tract infections, kidney stones, urethritis, blood cancer, bladder stones, prostate cancer, cystitis, trauma, vigorous exercise, polycystic kidney disease, endometriosis, and menstruation. Based on end user, the hematuria treatment market is segmented into hospitals, clinics, and Ambulatory Surgical Centers, and others. Geographically, the hematuria treatment market is segmented into Asia Pacific (China, Japan, India, South Korea, Australia, Rest of Asia Pacific).
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com